ScoreWhy is Concord Biotech Ltd ?
1
Flat results in Dec 24
- NET SALES(Q) At Rs 244.22 cr has Fallen at -10.0% (vs previous 4Q average)
- PBT LESS OI(Q) At Rs 86.42 cr has Fallen at -14.1% (vs previous 4Q average)
- PAT(Q) At Rs 75.92 cr has Fallen at -7.4% (vs previous 4Q average)
2
Stock is technically in a Bearish range
- The technical trend has deteriorated from Mildly Bearish on 07-Apr-25 and has generated 4.7% returns since then
- Multiple factors for the stock are Bearish like MACD, Bollinger Band and KST
3
With ROE of 20.6, it has a Very Expensive valuation with a 10.5 Price to Book Value
- Over the past year, while the stock has generated a return of 10.20%, its profits have risen by 28%
Real-Time Research ReportHow much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Drugs)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is Concord Biotech for you?
High Risk, Medium Return
Absolute
Risk Adjusted
Volatility
Concord Biotech
10.21%
0.21
48.01%
SENSEX
0.45%
0.03
14.48%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
19.40%
EBIT Growth (5y)
30.13%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
Net Debt is too low
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.64
Tax Ratio
25.80%
Dividend Payout Ratio
30.04%
Pledged Shares
0
Institutional Holding
17.99%
ROCE (avg)
27.41%
ROE (avg)
20.62%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
51
Industry P/E
33
Price to Book Value
10.53
EV to EBIT
41.50
EV to EBITDA
36.57
EV to Capital Employed
12.57
EV to Sales
15.12
PEG Ratio
NA
Dividend Yield
0.55%
ROCE (Latest)
30.87%
ROE (Latest)
20.62%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend0What is working for the Company
NO KEY POSITIVE TRIGGERS
-5What is not working for the Company
NET SALES(Q)
At Rs 244.22 cr has Fallen at -10.0% (vs previous 4Q average
PBT LESS OI(Q)
At Rs 86.42 cr has Fallen at -14.1% (vs previous 4Q average
PAT(Q)
At Rs 75.92 cr has Fallen at -7.4% (vs previous 4Q average
Loading Valuation Snapshot...
Here's what is not working for Concord Biotech
Net Sales - Quarterly
At Rs 244.22 cr has Fallen at -10.0% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 271.44 CrMOJO Watch
Near term sales trend is very negative
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 86.42 cr has Fallen at -14.1% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 100.59 CrMOJO Watch
Near term PBT trend is very negative
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 75.92 cr has Fallen at -7.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 81.98 CrMOJO Watch
Near term PAT trend is negative
PAT (Rs Cr)
Non Operating Income - Quarterly
Highest at Rs 14.73 cr
in the last five quartersMOJO Watch
Increased income from non business activities may not be sustainable
Non Operating Income
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
